With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP ...

Hoth Therapeutics (HOTH) announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for the treatment of dermatological conditions associated with ...

With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP), ...

(PRNewsfoto/Hoth Therapeutics Inc.) "These compelling findings reinforce GDNF's potential to fundamentally alter the way we approach obesity treatment," said Robb Knie CEO of Hoth Therapeutics.

Hoth Therapeutics (HOTH) announced “promising” findings for its novel therapeutic candidate, HT-001, a topical neurokinin 1 receptor antagonist, in the treatment of Epidermal Growth Factor ...

(RTTNews) - Hoth Therapeutics (HOTH) announced preclinical findings that highlight the potential of Glial Cell Line-Derived Neurotrophic Factor as a treatment for obesity. The study, conducted in ...

At a meeting on Feb. 20, the board of directors at the Organ Procurement and Transportation Network (OPTN) declared Memorial Hermann Hospital, University of Texas at Houston, a member not in good ...

Houston-based Memorial Hermann Health System has named Robert Mattix senior vice president and chief revenue officer, according to a March 3 post on his LinkedIn page. Mr. Mattix most recently ...

NEW YORK, March 4, 2025 /PRNewswire/ --Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced preclinical findings that highlight the potential of Glial ...